Sanofi Acquires BMP Sunstone To Expand Chinese Consumer Health Portfolio
This article was originally published in The Tan Sheet
Executive Summary
Sanofi-Aventis gains a leadership position in China's OTC cough/cold market with its $520.6 million acquisition of BMP Sunstone, the latest in the global pharma's parade of consumer health buys.
You may also be interested in...
Game Of Thrones: Bayer Looks To Lead China’s OTC Market
The recent acquisition of Dihon Pharmaceutical Group marks progress toward Bayer’s goal of becoming the leader in the OTC sector in China. Dihon provides an entry into the TCM arena, which makes up about half of the OTC segment in China, the firm says.
Game Of Thrones: Bayer Looks To Lead China’s OTC Market
The recent acquisition of Dihon Pharmaceutical Group marks progress toward Bayer’s goal of becoming the leader in the OTC sector in China. Dihon provides an entry into the TCM arena, which makes up about half of the OTC segment in China, the firm says.
Traditional Chinese Medicine Grows As Target For New Drug Opportunities
Nestle Health and Hutchison China MediTech’s JV has an ongoing phase III trial hoping to validate traditional Chinese medicine for Western health care systems. Reports of TCM contamination at China-based firms represent a market-incursion opportunity for Western firms with established supply chains.